Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2020-09-04
Original market date: See footnote 1
2020-09-04
Product name:
CABLIVI
DIN:
02496194
Product Monograph/Veterinary Labelling:
Date:
2021-03-24
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
SANOFI-AVENTIS CANADA INC
2905 Place Louis-R. Renaud
Laval
Quebec
Canada
H7V 0A3
Class:
Human
Dosage form(s):
Powder For Solution, Kit
Route(s) of administration:
Intravenous, Subcutaneous
Number of active ingredient(s):
1
Schedule(s):
Schedule D, Prescription
Biosimilar Biologic Drug:
No
American Hospital Formulary Service (AHFS): See footnote 3
20:12.92 ANTITHROMBOTIC AGENTS, MISC.
Anatomical Therapeutic Chemical (ATC): See footnote 4
B01AX07 CAPLACIZUMAB
Active ingredient group (AIG) number:See footnote 5
0162033001
| Active ingredient(s) | Strength |
|---|---|
| CAPLACIZUMAB | 11 MG / VIAL |